An investor asked on the investor interaction platform: it is said that the dioxane produced by the subsidiary senxuan medicine is the intermediate of the domestic Shanghai Junshi Biosciences Co.Ltd(688180) covid-19 specific drug. What is the annual production capacity of the subsidiary? Is there any need to expand production capacity in the future?
Jinghua Pharmaceutical Group Co.Ltd(002349) (002349. SZ) said on the investor interaction platform on January 11 that senxuan pharmaceutical, a subsidiary of the company, has no direct business relationship with Shanghai Junshi Biosciences Co.Ltd(688180) ; Dioxane is only used as a pharmaceutical chemical solvent. At present, the annual production capacity of senxuan pharmaceutical is 5000 tons. Senxuan pharmaceutical will determine whether to expand the relevant production capacity according to the future market demand, administrative license and many other factors.
(source: Daily Economic News)
